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REPLY: Platelets Interplay Between Pneumonia andCardiovascular Events
Establishing a Link?We appreciate the interest by Dr. Gavrillaki and col-
leagues in our editorial and their insightful comments.
First of all, Dr. Gavrillaki and colleagues indicate
that we support the infection hypothesis for athero-
sclerosis. We do not support such hypothesis, and
thus, this afﬁrmation was not stated in our editorial.
We do believe the role of inﬂammatory processes (not
necessarily infective) in the genesis and progression
of atherosclerosis (1). In fact, a variety of systemic
proinﬂammatory conditions increase the risk of
atherosclerotic cardiovascular events, including rhe-
umatoid arthritis, systemic lupus erythematosus,
or psoriatic arthritis (2). Furthermore, atherosclerosis
is aggravated by systemic inﬂammation of any etiol-
ogy, as the one seen after myocardial infarction (MI)
(3). It is in this context of atherosclerosis as asystemic inﬂammatory disease (but never of
atherosclerosis as caused by microorganisms) where
our comments about the pathophysiological link
between community-acquired pneumonia (CAP) and
MI should be placed. It is the systemic inﬂammatory
response originated by CAP and inﬂuenza infection
(and not the microorganism per se) that most likely
aggravates atherosclerosis burden and contribute to
the destabilization of atheroma plaques, thus
increasing the risk of MI. In fact, we do agree with
Dr. Gavrillaki and colleagues in the microorganism
theory having been refuted long ago (4).
Second, Dr. Gavrillaki and colleagues consider the
increased platelet activation in CAP patients devel-
oping MI because of the comorbidities of those pa-
tients, and thus already present even before the CAP.
Notwithstanding, Cangemi et al. (5) adjust in the
multivariate analysis for those baseline (i.e., pre-CAP)
comorbidities (age, sex, body mass index, diabetes,
hypertension, renal failure, previous MI or stroke,
peripheral artery disease), and they also test for
collinearity, so we can conclude that enhanced
platelet reactivity in CAP patients is independently
associated with MI even after adjusting for those
baseline comorbidities. That platelet aggregation is a
risk marker or a risk factor is a different story that
cannot be demonstrated statistically, only by trial
evidence, demonstrating that altering the risk factor
(platelet aggregation in CAP) changes the prognosis
(MI).
Finally, we do agree with Dr. Gavrillaki and col-
leagues regarding that platelet reactivity, not aggre-
gation, was assessed in the study by Cangemi et al.
(5). As they suggest, the monocyte–platelet aggre-
gates (MPA) are one marker of platelet activation that
could shed additional information on the link be-
tween platelet activation in CAP and MI. However,
heterotypic platelet aggregation (of which MPA is the
prime example) is not the only parameter to assess/
study platelet activation. Other markers such as ho-
motypic platelet aggregation (by light-transmission
aggregometry) or soluble serum markers (such as
the P-Selectin, CD40L, or TXB2 that Cangemi et al. [5]
used) are universally established/accepted, so the
choice of a speciﬁc marker does not change the
hypothesis-generating message of this article. Future
studies will undoubtedly analyze additional markers
of platelet activation (including MPA) to proﬁle in
depth the postulated mechanistic role of increased
platelet reactivity in MI incidence among CAP
patients.
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Myocardial Infarction in
Patients With PneumoniaWe have read with great interest the report by
Cangemi et al. (1) in a previous issue of the Journal.
The authors reported that myocardial infarction
(MI) is an early complication of pneumonia and
is associated with in vivo platelet activation and
serum thromboxane B2 (TxB2) overproduction. The
researchers found that the baseline serum TxB2
level was signiﬁcantly higher in patients who
develop signs of MI, and that in vivo platelet acti-
vation and overproduction of serum TxB2 formation
were independently associated with MI in a patient
with pneumonia. Also, the authors suggested that
increased TxB2 levels were associated with aspirin
resistance and increased plaque rupture. Although
important ﬁndings, some issues should be considered
in the interpretation of the study results.
The patient with pneumonia may have used
nonsteroidal anti-inﬂammatory drugs (NSAIDs) to
treat pain or fever. Previous studies in rats have
shown that NSAIDs affect the serum TxB2 level.
Akagi et al. (2) reported that NSAIDs (ibuprofen,
loxoprofen sodium, and etodolac) affect the serum
level of TxB2 in rats after oral administration. Also,
all NSAIDs can affect serum TxB2 levels because ofcyclooxygenase inhibition. However, the authors did
not mention the usage of NSAIDs on admission or
in hospital stay. Therefore, increased TxB2 levels
cannot be associated with MI. This issue should
be clariﬁed to correct the interpretation of study
results.
On the other hand, there are some doubts about
the diagnosis of MI. In the study, 24% of all patients
with pneumonia had renal failure. The patients
with renal failure had a high incidence of elevated
troponin levels of about 94%, and this could be
related with decreased glomerular ﬁltration rate. Li
et al. (3) stated that elevation of troponin T in chronic
renal failure was common (63.4%) in the absence of
MI deﬁned by the usual criteria. The researchers
concluded that troponins and electrocardiography
(ECG) were necessary to detect MI. However, the
characteristics of ECG changes were unknown. Stein
et al. (4) reported that in pneumonia patients without
previous cardiopulmonary disease, ECGs show ST-
segment or T-wave changes (21%). Therefore, the
characteristics of ECG changes and the results of
troponin monitoring should be explained before
commenting on the study results.*Goktug Savas, MD
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Cardiol 2012;15:1836–40.REPLY: Myocardial Infarction inPatients With PneumoniaWe thank Drs. Savas and Kalay for their interest in our
paper (1).
Epidemiological studies have shown that respira-
tory tract infections are associated with an increased
risk for the development of artery thrombosis as
